Immunosuppressant-driven de novo malignant neoplasms after solid-organ transplant

Progress in Transplantation

Volumn 25, Issue 2, 2015, Pages 182-188

  Billups, Kelsey ^a   Neal, Jennifer ^a   Salyer, Jeanne ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ADVERSE EFFECTS; DRUG EFFECTS; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; NEOPLASMS; RISK FACTOR; TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; NEOPLASMS; RISK FACTORS; TRANSPLANTS;

EID: 84946846612     PISSN: 15269248     EISSN: 21646708     Source Type: Journal    
DOI: 10.7182/pit2015826     Document Type: Article

References (41)

1. Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant. 2007;22 (suppl 1):i4-10.
2. Campistol JM, Cuervas-Mons V, Manito N, et al. New concepts and best practices for management of pre- and posttransplantation cancer. Transplant Rev. 2012;26(4):261-279.
3. US Department of Health and Human Services. Organ Procurement and Transplantation Network. http://optn.transplant.hrsa.gov/. Accessed October 28, 2014
4. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation. 2005;80(2 suppl):S254-264.
5. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-1570.
6. Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumor virology. Nat Rev Cancer. 2010;10(12):878-889. doi:10.1038/nrc2961.
7. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs. 2007;67(8):1167-1198.
8. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in Cancer. Front Oncol. 2014;4:64.
9. Stallone G, Schena A, Infante B, et al. Sirolimus for Kapo si'ssarcoma in renal transplant recipients. N Engl J Med. 2005; 352(13):1317-1323.
10. Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in sold organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 2005;56(1):23-46.
11. Rutz HP, Herr I. Interference of glucocorticoids with apoptosis signaling and host-tumor interactions. Cancer Biol Ther. 2004;3(8):715-718.
12. Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst. 2004;96(9):709-711.
13. O'Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005;309(5742):1871-1874.
14. Martinez OM, de Gruijl FR. Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. Am J Transplant. 2008;8(11):2205-2211.
15. Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood. 2004;104(3): 822-828.
16. Blaheta RA, Bogossian H, Beecken WD, et al. Mycophenolate mofetil increases adhesion capacity of tumor cells in vitro. Transplantation. 2003;76(12):1735-1741.
17. Ming M, Zhao B, Qiang L, He YY. Effect of immunosuppressants Tacrolimus and Mycophenolate Mofetil on the Keratinocyte UVB response. Photochem Photobiol. 2014; doi:10.1111/php.12318.
18. Dandel M, Jasaityte R, Lehmkuhl H, Knosalla C, Hetzer R. Maintenance immunosuppression with mycophenolate mofetil: long-term efficacy and safety after heart transplantation. Transplant Proc. 2009;41(6):2585-2588.
19. Molina BD, Leiro MG, Pulpón LA, et al. Incidence and risk factors for nonmelanoma skin cancer after heart transplantation. Transplant Proc. 2010;42(8):3001-3005.
20. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttrasplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation. 2003;76(9):1289-1293.
21. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant. 2005;5(12):2954-2960.
22. Rush D. The impact of calcineurin inhibitors on graft survival. Transplant Rev. 2013;27(3):93-95.
23. Penn I. Post-transplant malignancy: the role of immunosuppres sion.Drug Saf. 2000;23(2):101-113.
24. Tanner JE, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis. 2001;3(2):60-69.
25. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000; 342(18):1350-1358.
26. Fuchs U, Klein S, Zittermann A, et al. Incidence of malignant neoplasia after heart transplantation-a comparison between cyclosporine a and tacrolimus. Ann Transplant. 2014;19:300-304. doi:10.12659/AOT.890199.
27. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation. 2003;76(3):597-602.
28. Moffatt SD, Metcalfe SM. Comparison between tacrolimus and cyclosporine as immunosuppressive agents compatible with tolerance induction by CD4/CD8 blockade. Transplantation. 2000;69(8):1724-1726.
29. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2):128-135.
30. Koehl GE, Andrassy J, Guba M, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation. 2004;77(9):1319-1326.
31. Euvrard S, Kanitakis J, Pouteil-Noble C, Claudy A, Touraine JL. Skin cancers in organ transplant recipients. Ann Transplant. 1997;2(4):28-32.
32. Penn I. Kaposi's sarcoma in transplant recipients. Transplantation. 1997;64(5):669-673.
33. Tan HH, Goh CL. Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies. Am J Clin Dermatol. 2006;7(1):13-29.
34. Zimmermann H, Trappe RU. EBV and posttransplantation lymphoproliferative disease: what to do? Hematol Am Soc Hematol Educ Program. 2013;2013:95-102.
35. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(suppl 3):S1-S155.
36. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation. 2008;85(12): 1675-1685.
37. Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: monitoring and patient education-2012. Am J Health Syst Pharm. 2013;70(9):787-803. doi:10.2146/ajhp120777.
38. Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M. Malignancy in renal transplantation. J Am Soc Nephrol. 2004;15(6):1582-1588.
39. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006;17(2):581-589.
40. Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891-1901.
41. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with posttransplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010; 28(6):1038-1046.